2024年第四季度Voyager Therapeutics GAAP每股收益$(0.59)不及预期$(0.38),销售额$627.8万不及预期$1657.7万

财报速递
12 Mar
Voyager Therapeutics (纳斯达克代码: VYGR) 报告季度每股亏损$(0.59),不及分析师一致预期的$(0.38),差距为55.26%。相比去年同期每股收益$1.25,这次下降了147.2%。公司季度销售额为$627.8万,也不及分析师一致预期的$1657.7万,差距为62.13%。相比去年同期的$9006.1万,下降了93.03%。

以上内容来自Benzinga Earnings专栏,原文如下:

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.38) by 55.26 percent. This is a 147.2 percent decrease over earnings of $1.25 per share from the same period last year. The company reported quarterly sales of $6.278 million which missed the analyst consensus estimate of $16.577 million by 62.13 percent. This is a 93.03 percent decrease over sales of $90.061 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10